Perspective Therapeutics (CATX) updates radiopharmaceutical oncology pipeline presentation
Rhea-AI Filing Summary
Perspective Therapeutics, Inc. filed an 8-K to note that it updated its corporate presentation on July 1, 2026. The new presentation highlights its focus on next-generation radiopharmaceuticals for oncology, centered on 212Pb-based therapies and an integrated production and delivery model.
The materials describe a diverse pipeline targeting solid tumors, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma, and PSV359 for FAP-α–expressing solid tumors, all in ongoing phase 1/2a trials. The deck also emphasizes a theranostic approach, regional manufacturing, and direct-to-hospital delivery to support ready-to-administer products.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
radiopharmaceuticals medical
theranostic approach medical
Phase 1/2a medical
radioligand therapy medical
SSTR2+ Neuroendocrine Tumors medical
immune check point inhibitors medical
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On July 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
99.1 |
|
Corporate Presentation. |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PERSPECTIVE THERAPEUTICS, INC. |
|
|
|
|
Date: |
July 1, 2026 |
By: |
/s/ Joel Sendek |
|
|
|
Joel Sendek |
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Engineering the Alpha Advantage in Targeted Oncology
Unlocking New Treatment Options Across Solid Tumors:
Optimizing the Entire System
Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Optimizing Structural Chemistry:
Choosing The Right Isotope
Not All ²¹²Pb Programs Are Created Equal
Advancing a Theranostic Approach:
Solid Tumors are an Attractive Market for Radiopharmaceuticals
Expanding the Addressable Market
Direct-to-Hospital Delivery through Integrated Isotope Production
Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product
Reaching the Largest Addressable Market with Regional Manufacturing
Advancing a Diverse 212Pb-Based Oncology Portfolio
SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-⍺-NET in NETs
VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis
Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis
VMT-α-NET Best Response Deepens Over Time
VMT-α-NET Responses Deepen Over Time
VMT-⍺-NET: Durable Disease Control Across All Doses
Spider Plot of Tumor Change Over Time by Patient
Best-in-class Safety Profile1
Blood Creatinine During Follow-up for All Patients Treated (n=68)
VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level
Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind
VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma
Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01
Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)
VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development
FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential
PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors
Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors
PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent
Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain
A Decade of Deliberate, End-to-End Engineering
Built Over a Decade:
Abbreviations
APPENDIX
NETs Trials
Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment
Refractory Metastatic Melanoma Trials
ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma
Metastatic Melanoma: Confirmed Partial Response after 2 Cycles of [212Pb]VMT01
Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa
Construct designed for better clinical outcome
212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors
Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure
